Boston Partners’s Nutrien NTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$216M Sell
2,133,479
-833,700
-28% -$59.5M 0.23% 150
2025
Q4
$245M Sell
2,967,179
-280,365
-9% -$16.5M 0.25% 142
2025
Q3
$260M Buy
3,247,544
+664,855
+26% +$38.8M 0.27% 129
2025
Q2
$202M Buy
+2,582,689
New +$146M 0.22% 151
2020
Q4
Sell
-23,053
Closed -$904K 664
2020
Q3
$904K Sell
23,053
-1,158,023
-98% -$42.2M ﹤0.01% 548
2020
Q2
$37.9M Sell
1,181,076
-1,307,916
-53% -$45.5M 0.07% 243
2020
Q1
$84.5M Sell
2,488,992
-1,352,940
-35% -$54.2M 0.17% 158
2019
Q4
$184M Buy
3,841,932
+97,277
+3% +$4.7M 0.24% 118
2019
Q3
$187M Sell
3,744,655
-6,361,375
-63% -$325M 0.25% 117
2019
Q2
$540M Sell
10,106,030
-2,478,842
-20% -$129M 0.71% 36
2019
Q1
$664M Buy
12,584,872
+3,556,556
+39% +$185M 0.88% 27
2018
Q4
$424M Buy
9,028,316
+155,876
+2% +$8.13M 0.61% 45
2018
Q3
$512M Buy
8,872,440
+184,699
+2% +$10.2M 0.59% 49
2018
Q2
$472M Buy
8,687,741
+496,801
+6% +$24.6M 0.57% 50
2018
Q1
$387M Buy
+8,190,940
New +$410M 0.47% 68

Other funds holding NTR

Boston Partners's NTR Position: Q1 2026 in Review

Boston Partners reduced its Nutrien (NTR) stake by 28% in Q1 2026, selling an estimated $59.5M and leaving 2,133,479 shares worth $216M. The position accounts for 0.23% of the portfolio, ranked #150.

Boston Partners first reported a position in NTR in Q1 2018 and has held it in 15 quarters since. The position peaked at $664M in Q1 2019. 747 funds tracked by Wall St. Rank hold NTR as of Q1 2026.

  • Boston Partners held 2,133,479 shares of Nutrien worth $216M as of Q1 2026.
  • Boston Partners sold 833,700 Nutrien shares in Q1 2026, an estimated $59.5M.
  • Nutrien made up 0.23% of Boston Partners's portfolio in Q1 2026, its #150 holding.
  • Boston Partners first reported a position in Nutrien in Q1 2018 and has held it in 15 quarters since.
  • Boston Partners's Nutrien position peaked at $664M in Q1 2019.
  • 747 funds tracked by Wall St. Rank held Nutrien as of Q1 2026.

Based on Boston Partners's 13F filing for Q1 2026, filed 11 May 2026.